title: Occult breast tumor reservoir: biological properties and clinical significance.
abstract: Small, occult, undiagnosed breast cancers are found at autopsy in up to 15.6 % of women dying from unrelated causes with an average of 7 % from eight separate studies. The mammographic detection threshold of breast tumors ranges from 0.88 to 1.66 cm in diameter based on the patient's age. Tumor growth rates, expressed as "effective doubling times," vary from 10 to >700 days. We previously reported two models, based on iterative analysis of these parameters, to describe the biologic behavior of undiagnosed, occult breast tumors. Our models facilitate interpretation of the Women's Health Initiative (WHI) and antiestrogen breast cancer prevention studies. A nude mouse xenograft model was used to validate our assumption that breast tumors grow in a log-linear fashion. We then used our previously reported occult tumor growth (OTG) and computer-simulated tumor growth models to analyze various clinical trial data. Parameters used in the OTG model included a 200-day effective doubling time, 7 % prevalence of occult tumors, and 1.16 cm detection threshold. These models had been validated by comparing predicted with observed incidence of breast cancer in eight different populations of women. Our model suggests that menopausal hormone therapy with estrogens plus a progestogen (E + P) in the WHI trial primarily promoted the growth of pre-existing, occult lesions and minimally initiated de novo tumors. We provide a potential explanation for the lack of an increase in breast cancer incidence in the subgroup of women in the WHI who had not received E + P prior to randomization. This result may have reflected a leftward skew in the distribution of occult tumor doublings and insufficient time for stimulated tumors to reach the detection threshold. Our model predicted that estrogen alone reduced the incidence of breast cancer as a result of apoptosis. Understanding of the biology of occult tumors suggests that breast cancer "prevention" with antiestrogens or aromatase inhibitors represents early treatment rather than a reduction in de novo tumor formation. Our models suggest that occult, undiagnosed tumors are prevalent, grow slowly, and are the biologic targets of a hormone therapy in menopausal women and of antiestrogen therapy for prevention.
authors: Department of Internal Medicine, Division of Endocrinology, University of Virginia, Charlottesville, VA 22908-1416, USA. rjs5y@virginia.edu
authors: Richard J
authors: RJ
authors: Santen
authors: Wei
authors: W
authors: Yue
authors: Daniel F
authors: DF
authors: Heitjan
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000453:epidemiology / Q000473:pathology* / Q000517:prevention & control; D049109:Cell Proliferation; D003198:Computer Simulation; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D008954:Models, Biological; D009368:Neoplasm Transplantation; D009376:Neoplasms, Hormone-Dependent / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D012306:Risk; D013629:Tamoxifen / Q000008:administration & dosage*; D016896:Treatment Outcome; D047368:Tumor Burden
chemical_list: D018931:Antineoplastic Agents, Hormonal; D004967:Estrogens; D013629:Tamoxifen
references: JAMA. 2006 Jun 21;295(23):2727-41
references: 16754727
references: J Natl Cancer Inst. 2010 May 5;102(9):605-13
references: 20413742
references: J Natl Cancer Inst. 2012 Jul 18;104(14):1080-93
references: 22811439
references: J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):891-6
references: 1314086
references: Radiology. 2011 Sep;260(3):621-7
references: 21846758
references: Apoptosis. 2005 May;10(3):667-78
references: 15909128
references: N Engl J Med. 2011 Jun 23;364(25):2381-91
references: 21639806
references: J Clin Oncol. 2010 Mar 1;28(7):1161-7
references: 20124184
references: Breast Cancer Res Treat. 2011 Apr;126(3):729-38
references: 20872242
references: Arch Pathol Lab Med. 2000 Mar;124(3):378-81
references: 10705389
references: Lancet. 2012 Nov 17;380(9855):1778-86
references: 23117178
references: Menopause. 2012 Apr;19(4):479-85
references: 22278343
references: Surgery. 1989 Nov;106(5):904-10
references: 2814824
references: Climacteric. 2012 Oct;15(5):411-8
references: 22853444
references: Climacteric. 2010 Apr;13(2):132-40
references: 19863455
references: Mol Endocrinol. 2009 Jan;23(1):74-85
references: 19036900
references: J Clin Endocrinol Metab. 2010 Jul;95(7 Suppl 1):s1-s66
references: 20566620
references: J Natl Cancer Inst Monogr. 2006;(36):56-65
references: 17032895
references: Cancer. 1987 Dec 1;60(11):2751-60
references: 3677009
references: Menopause. 2009 Nov-Dec;16(6):1109-15
references: 19543129
references: JAMA. 2002 Jul 17;288(3):321-33
references: 12117397
references: J Steroid Biochem Mol Biol. 2009 Mar;114(1-2):33-9
references: 19167492
references: Cancer Prev Res (Phila). 2011 May;4(5):633-7
references: 21478501
references: Maturitas. 2006 Sep 20;55(2):103-15
references: 16815651
references: Menopause. 2010 Mar;17(2):281-9
references: 19779382
references: J Natl Cancer Inst. 1975 Aug;55(2):231-73
references: 169369
references: J Natl Cancer Inst. 1998 Sep 16;90(18):1371-88
references: 9747868
references: Cancer Prev Res (Phila). 2010 Jun;3(6):696-706
references: 20404000
references: JAMA. 2010 Oct 20;304(15):1684-92
references: 20959578
references: JAMA. 2006 Apr 12;295(14):1647-57
references: 16609086
references: J Natl Cancer Inst. 2005 Nov 16;97(22):1652-62
references: 16288118
references: Lancet Oncol. 2012 May;13(5):476-86
references: 22401913
references: J Clin Oncol. 2008 Jun 20;26(18):3073-82
references: 18519949
references: J Clin Endocrinol Metab. 1995 Oct;80(10):2918-25
references: 7559875
references: BMJ. 2009 Jul 09;339:b2587
references: 19589821
references: Clin Breast Cancer. 2008 Apr;8(2):124-33
references: 18621608
references: Breast Cancer Res. 2009;11(3):206
references: 19519952
references: Hum Pathol. 1985 Aug;16(8):796-807
references: 2991111
references: Cancer. 2003 Jun 15;97(12):2951-9
references: 12784329
references: Cancer. 1964 Dec;17:1501-27
references: 14239677
references: Br J Cancer. 1987 Dec;56(6):814-9
references: 2829956
references: Endocrinology. 2012 Dec;153(12):5706-15
references: 23070546
references: Br J Cancer. 1985 Feb;51(2):271-8
references: 3966983
references: JAMA. 2003 Jun 25;289(24):3243-53
references: 12824205
references: J Natl Cancer Inst. 2001 Nov 21;93(22):1714-23
references: 11717332
references: Arch Intern Med. 2008 Nov 24;168(21):2311-6
references: 19029493
references: J Clin Endocrinol Metab. 2008 Sep;93(9):3295-8
references: 18647813
references: Clin Cancer Res. 2011 Aug 1;17(15):4948-58
references: 21791635
references: Cancer. 1995 Jan 1;75(1):43-6
references: 7804976
references: J Natl Cancer Inst. 2005 Dec 7;97(23):1746-59
references: 16333030
references: Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1038-48
references: 22586072
references: N Engl J Med. 2009 Feb 5;360(6):573-87
references: 19196674
references: J Surg Oncol. 1996 Jan;61(1):68-83
references: 8544465
references: J Natl Cancer Inst. 2010 May 19;102(10):665-8
references: 20427429
references: Ann Intern Med. 1997 Dec 1;127(11):1023-8
references: 9412284
references: Fertil Steril. 2009 Sep;92(3):1045-1052
references: 19635616
references: Endocrinology. 2013 Feb;154(2):656-65
references: 23254198
references: PLoS One. 2011;6(6):e20410
references: 21738574
references: J Natl Cancer Inst. 2010 May 19;102(10):680-91
references: 20427433
references: Int J Womens Health. 2012;4:129-40
references: 22505832
references: Menopause. 2009 Nov-Dec;16(6):1116-24
references: 19546826
references: Apoptosis. 2003 Jan;8(1):55-60
references: 12510152
references: JAMA. 2011 Apr 6;305(13):1305-14
references: 21467283
references: J Clin Oncol. 2010 Dec 10;28(35):5140-6
references: 21060026